480 related articles for article (PubMed ID: 25249380)
1. Dyspnea, relative youth and low daily doses of opioids predict increased opioid dosage in the last week of a terminal cancer patient's life.
Miura T; Matsumoto Y; Motonaga S; Hasuo H; Abe K; Kinoshita H
Jpn J Clin Oncol; 2014 Nov; 44(11):1082-7. PubMed ID: 25249380
[TBL] [Abstract][Full Text] [Related]
2. Opioids for Relief of Dyspnea Immediately Before Death in Patients With Noncancer Disease: A Case Series Study.
Murakami M
Am J Hosp Palliat Care; 2019 Aug; 36(8):734-739. PubMed ID: 30803242
[TBL] [Abstract][Full Text] [Related]
3. Clinical experience with transdermal and orally administered opioids in palliative care patients--a retrospective study.
Clemens KE; Klaschik E
Jpn J Clin Oncol; 2007 Apr; 37(4):302-9. PubMed ID: 17519302
[TBL] [Abstract][Full Text] [Related]
4. Opioid use in palliative care of children and young people with cancer.
Hewitt M; Goldman A; Collins GS; Childs M; Hain R
J Pediatr; 2008 Jan; 152(1):39-44. PubMed ID: 18154896
[TBL] [Abstract][Full Text] [Related]
5. Inappropriate use of high doses of transdermal fentanyl at admission to a palliative care unit.
Botterman J; Criel N
Palliat Med; 2011 Mar; 25(2):111-6. PubMed ID: 20937611
[TBL] [Abstract][Full Text] [Related]
6. Morphine for dyspnea control in terminal cancer patients: is it appropriate in Taiwan?
Hu WY; Chiu TY; Cheng SY; Chen CY
J Pain Symptom Manage; 2004 Oct; 28(4):356-63. PubMed ID: 15471653
[TBL] [Abstract][Full Text] [Related]
7. Opioid prescription for terminally ill outpatients in a district of northern Italy: a retrospective survey.
Salvato C; Aretini G; Serraglia D; Terrazzani G; Debetto P; Giusti P; Chinellato A
Pharmacol Res; 2003 Jul; 48(1):75-82. PubMed ID: 12770518
[TBL] [Abstract][Full Text] [Related]
8. A Clinical Study on Administration of Opioid Antagonists in Terminal Cancer Patients: 7 Patients Receiving Opioid Antagonists Following Opioids among 2443 Terminal Cancer Patients Receiving Opioids.
Uekuzu Y; Higashiguchi T; Futamura A; Ito A; Mori N; Murai M; Ohara H; Awa H; Chihara T
Biol Pharm Bull; 2017 Mar; 40(3):278-283. PubMed ID: 27980244
[TBL] [Abstract][Full Text] [Related]
9. Methadone titration in opioid-resistant cancer pain.
Scholes CF; Gonty N; Trotman IF
Eur J Cancer Care (Engl); 1999 Mar; 8(1):26-9. PubMed ID: 10362950
[TBL] [Abstract][Full Text] [Related]
10. Combined Effect of Opioids and Corticosteroids for Alleviating Dyspnea in Terminal Cancer Patients: A Retrospective Review.
Maeda T; Hayakawa T
J Pain Palliat Care Pharmacother; 2016 Jun; 30(2):106-10. PubMed ID: 27093633
[TBL] [Abstract][Full Text] [Related]
11. Rapid increase of morphine and benzodiazepine usage in the last three days of life in children with cancer is related to neuropathic pain.
Dougherty M; DeBaun MR
J Pediatr; 2003 Apr; 142(4):373-6. PubMed ID: 12712053
[TBL] [Abstract][Full Text] [Related]
12. Intravenous morphine consumption in outpatients with cancer during their last week of life--an analysis based on patient-controlled analgesia data.
Schiessl C; Sittl R; Griessinger N; Lutter N; Schuettler J
Support Care Cancer; 2008 Aug; 16(8):917-23. PubMed ID: 17960428
[TBL] [Abstract][Full Text] [Related]
13. Morphine prescription to terminally ill patients with lung cancer and dyspnea: French physicians' attitudes.
Bendiane MK; Peretti-Watel P; Pegliasco H; Favre R; Galinier A; Lapiana JM; Obadia Y
J Opioid Manag; 2005; 1(1):25-30. PubMed ID: 17315408
[TBL] [Abstract][Full Text] [Related]
14. Oral morphine as symptomatic treatment of dyspnoea in patients with advanced cancer.
Boyd KJ; Kelly M
Palliat Med; 1997 Jul; 11(4):277-81. PubMed ID: 9373578
[TBL] [Abstract][Full Text] [Related]
15. Factors predicting requirement of high-dose transdermal fentanyl in opioid switching from oral morphine or oxycodone in patients with cancer pain.
Kanbayashi Y; Hosokawa T; Okamoto K; Fujimoto S; Konishi H; Otsuji E; Yoshikawa T; Takagi T; Miki T; Taniwaki M
Clin J Pain; 2011 Oct; 27(8):664-7. PubMed ID: 21471811
[TBL] [Abstract][Full Text] [Related]
16. The intravenous to oral relative milligram potency ratio of morphine during chronic dosing in cancer pain.
Lasheen W; Walsh D; Mahmoud F; Sarhill N; Rivera N; Davis M; Lagman R; Legrand S
Palliat Med; 2010 Jan; 24(1):9-16. PubMed ID: 19910396
[TBL] [Abstract][Full Text] [Related]
17. Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio?
Ripamonti C; Groff L; Brunelli C; Polastri D; Stavrakis A; De Conno F
J Clin Oncol; 1998 Oct; 16(10):3216-21. PubMed ID: 9779694
[TBL] [Abstract][Full Text] [Related]
18. Addition of a second opioid may improve opioid response in cancer pain: preliminary data.
Mercadante S; Villari P; Ferrera P; Casuccio A
Support Care Cancer; 2004 Nov; 12(11):762-6. PubMed ID: 15206014
[TBL] [Abstract][Full Text] [Related]
19. High dose morphine use in the hospice setting. A database survey of patient characteristics and effect on life expectancy.
Bercovitch M; Waller A; Adunsky A
Cancer; 1999 Sep; 86(5):871-7. PubMed ID: 10463988
[TBL] [Abstract][Full Text] [Related]
20. The Conversion Ratio From Intravenous Hydromorphone to Oral Opioids in Cancer Patients.
Reddy A; Vidal M; Stephen S; Baumgartner K; Dost S; Nguyen A; Heung Y; Kwan S; Wong A; Pangemanan I; Azhar A; Tayjasanant S; Rodriguez E; Waletich J; Lim KH; Wu J; Liu D; Williams J; Yennurajalingam S; Bruera E
J Pain Symptom Manage; 2017 Sep; 54(3):280-288. PubMed ID: 28711751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
